Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

With the quadruple therapy. And then, as you know, in myeloma, we consolidate our patients with autologous stem cell transplantation, which is the standard of care. So now in this study ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

which showed that D-VRd led to significant improvement in PFS compared with VRd alone in patients with newly diagnosed multiple myeloma eligible for stem cell transplant, and led to the regimen's ...

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say ...

Films like Strong: Living with Multiple Myeloma are essential. Multiple Myeloma is not exactly high on the list of diseases ...

Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after ...

Multiple Genetic Abnormalities Lead to Poor Prognosis Around 5900 people are diagnosed with myeloma each year ... chemotherapy, and stem cell transplants. More than half of patients survive ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...